Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (39)
Jia xiang Jin
1Heidelberg Myeloma Center and German-speaking Myeloma Multicenter Group (GMMG), Heidelberg University Hospital, Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg, Germany
Varun R. Ginde
Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany
Stefanie Huhn
1Heidelberg Myeloma Center and German-speaking Myeloma Multicenter Group (GMMG), Heidelberg University Hospital, Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg, Germany
Philipp Reichert
1Heidelberg Myeloma Center and German-speaking Myeloma Multicenter Group (GMMG), Heidelberg University Hospital, Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg, Germany
Uta Bertsch
1Heidelberg Myeloma Center and German-speaking Myeloma Multicenter Group (GMMG), Heidelberg University Hospital, Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg, Germany
Roland Fenk
4University Hospital Düsseldorf, Department of Hematology, Oncology and Clinical Immunology, Düsseldorf, Germany
Britta Besemer
Department of Internal Medicine II, University Tübingen, Tübingen, Germany
Amelie Boquoi
6University Hospital Essen, Department for Hematology and Stem Cell Transplantation, Essen, Germany
Roland Schroers
18Medical Clinic II-Hematology and Oncology, Ruhr-University Bochum, Bochum, Germany
Ivana von Metzler
Mathias Hänel
7Department III of Internal Medicine, Klinikum Chemnitz, Chemnitz, Germany
Christoph Mann
10University Hospital Gießen and Marburg, Department for Hematology, Oncology and Immunology, Marburg, Germany
Lisa B. Leypoldt
Department of Oncology, Hematology and BMT, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Bernhard Heilmeier
12Hospital Barmherzige Brueder Regensburg, Clinic for Oncology and Hematology, Regensburg, Germany
Christof Scheid
12Hospital Barmherzige Brueder Regensburg, Clinic for Oncology and Hematology, Regensburg, Germany
Thorsten Peters-Regehr
13The Binding Site GmbH, part of Thermo Fisher Scientific, Schwetzingen, Germany
Igor W. Blau
Carsten Müller-Tidow
Steffen Luntz
15Coordination Centre for Clinical Trials (KKS) Heidelberg, Heidelberg, Germany
Tobias A.W. Holderried
16University Hospital Bonn, Department of Hematology, Oncology, Stem Cell Transplantation, Immune and Cell Therapy, Clinical Immunology and Rheumatology, Bonn, Germany
Karolin Trautmann-Grill
3Department of Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany
Deniz Gezer
18RWTH Aachen University, Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, Aachen, Germany
Maika Klaiber-Hakimi
19Marien Hospital Düsseldorf, Clinic for Hematology, Oncology and Palliative Care, Düsseldorf, Germany
Martin Müller
Evgenii Shumilov
1University Hospital Muenster, Department of Medicine A, Hematology, Oncology and Pneumology, Muenster, Germany
Wolfgang Knauf
28Centrum für Hämatologie und Onkologie Bethanien, Frankfurt am Main, Germany
Christian S. Michel
1Department of Hematology and Oncology, Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
Thomas Geer
24Diakoneo Clinic Schwäbisch-Hall, Department of Internal Medicine III, Schwäbisch-Hall, Germany
Hendrik Riesenberg
25Hematology/Oncology Center, Bielefeld, Germany
Christoph Lutz
Marc S. Raab
Niels Weinhold
Martin Hoffmann
Axel Benner
Peter Findeisen
28MVZ Labor Dr. Limbach und Kollegen, Heidelberg, Germany
Katja C. Weisel
Hans J. Salwender
20Asklepios Tumorzentrum Hamburg, AK Altona and AK St. Georg, Hamburg, Germany
Elias K. Mai
Hartmut Goldschmidt
Internal Medicine V, Hematology, Oncology and Rheumatology, German-Speaking Myeloma Multicenter Group Study Group, Heidelberg University Hospital and National Center for Tumor Diseases, Heidelberg, Germany